The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Clinical Outcomes and Correlates of TP53 Mutations and Cancer
Open accessAbstract
The initial observation that p53 accumulation might serve as a surrogate biomarker for TP53 mutation has been the cornerstone for vast translational efforts aimed at validating its clinical use for the diagnosis, prognosis, and treatment of cancer. Early on, it was realized that accurate evaluation of p53 status and function could not be achieved through protein-expression analysis only. As our understanding of the p53 pathway has evolved and more sophisticated methods for assessment of p53 functional integrity have become available, the clinical and molecular epidemiological implications of p53 abnormalities in cancers are being revealed. They include diagnostic testing for germline p53 mutations, and the assessment of selected p53 mutations as biomarkers of carcinogen exposure and cancer risk and prognosis. Here, we describe the strengths and limitations of the most frequently used techniques for determination of p53 status in tumors, as well as the most remarkable latest findings relating to its clinical and epidemiological value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationThe p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
A role for sunlight in skin-cancer – UV-induced p53 mutations in squamous-cell carcinoma
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., & Pontén, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10124 · Cited by 1,959
Ambros, V. (2001) · Cell · doi:10.1016/s0092-8674(01)00616-x · Cited by 1,697
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“fr) using the provided bioinformatics tools (Petitjean et al. 2007).”
BackgroundMutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Self-citationSenescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Self-citationWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Inflammation and cancer: An ancient link with novel potentials
Perwez Hussain, S., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,097
Self-citationA microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078
MicroRNA-Cancer Connection: The Beginning of a New Tale
Calin, G. A., & Croce, C. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0800 · Cited by 1,053
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer
Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 974
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
Poeta, M. L., Manola, J., Goldwasser, M. A., Forastiere, A., Benoit, N., Califano, J. A., Ridge, J. A., Goodwin, J., Kenady, D., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 817
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically
Thomas, M., Kalita, A., Labrecque, S., Pim, D., Banks, L., & Matlashewski, G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1092 · Cited by 701
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
MicroRNA-125b is a novel negative regulator of p53
Le, M. T. N., Teh, C., Shyh-Chang, N., Xie, H., Zhou, B., Korzh, V., Lodish, H. F., & Lim, B. (2009) · Genes & Development · doi:10.1101/gad.1767609 · Cited by 655
Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 621
Self-citationBeyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 606
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
MicroRNAs: Novel Biomarkers for Human Cancer
Bartels, C. L., & Tsongalis, G. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112805 · Cited by 529
An overview of prognostic factors for long-term survivors of breast cancer
Soerjomataram, I., Louwman, M. W. J., Ribot, J. G., Roukema, J. A., & Coebergh, J. W. W. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9556-1 · Cited by 513
Aguilar, F., Hussain, S. P., & Cerutti, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8586 · Cited by 489
Hussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., Shields, P. G., Ham, A. L., Swenberg, J. A., Marrogi, A. J., et al. (2000) · PubMed · Cited by 482
Self-citationRusso, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T., & Gebbia, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.471 · Cited by 416
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation
Hofseth, L. J., Saito, S., Hussain, S. P., Espey, M. G., Miranda, K. M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S. P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237083100 · Cited by 355
Self-citationp53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
Self-citationRossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1630 · Cited by 310
TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Langerød, A., Zhao, H., Borgan, Ø., Nesland, J. M., Bukholm, I. R., Ikdahl, T., Kåresen, R., Børresen-Dale, A.-L., & Jeffrey, S. S. (2007) · Breast Cancer Research · doi:10.1186/bcr1675 · Cited by 291
P53 abnormalities and outcomes in colorectal cancer: a systematic review
Munro, A. J., Lain, S., & Lane, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602358 · Cited by 289
Ambs, S., Merriam, W. G., Ogunfusika, M. O., Bennett, W. P., Ishibe, N., Hussain, S. P., Tzeng, E. E., Geller, D. A., Billiar, T. R., & Harris, C. C. (1998) · Nature Medicine · doi:10.1038/3957 · Cited by 287
Self-citationp53 Mutations in non-small cell lung cancer in Japan: Association between mutations and smoking
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90041-h · Cited by 275
Hepatocellular Carcinoma: From Gene to Public Health
Montesano, R., Hainaut, P., & Wild, C. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.24.1844 · Cited by 269
Bousquet, M., Quelen, C., Rosati, R., Mansat-De Mas, V., La Starza, R., Bastard, C., Lippert, E., Talmant, P., Lafage-Pochitaloff, M., Leroux, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080285 · Cited by 248
Hussain, S. P., Raja, K., Amstad, P. A., Sawyer, M., Trudel, L. J., Wogan, G. N., Hofseth, L. J., Shields, P. G., Billiar, T. R., Trautwein, C., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220416097 · Cited by 248
Self-citationTP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Self-citationAmbs, S., Hussain, S. P., & Harris, C. C. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194524 · Cited by 233
Self-citationMolecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array
Ahrendt, S. A., Halachmi, S., Chow, J. T., Wu, L., Halachmi, N., Yang, S. C., Wehage, S., Jen, J., & Sidransky, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7382 · Cited by 230
p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study
Ahrendt, S. A., Hu, Y., Buta, M., McDermott, M. P., Benoit, N., Yang, S. C., Wu, L., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.961 · Cited by 222
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Young, K. H., Leroy, K., Møller, M. B., Colleoni, G. W. B., Sánchez-Beato, M., Kerbauy, F. R., Haioun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., et al. (2008) · Blood · doi:10.1182/blood-2008-01-129783 · Cited by 191
The p53 codon 72 polymorphism and lung cancer risk.
Fan, R., Wu, M., MILLER, D. P., Wain, J. C., Kelsey, K. T., Wiencke, J. K., & Christiani, D. C. (2000) · PubMed · Cited by 183
Kirk, G. D., Lesi, O. A., Mendy, M., Szymañska, K., Whittle, H., Goedert, J. J., Hainaut, P., & Montesano, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208732 · Cited by 181
Bertheau, P., Turpin, E., Rickman, D. S., Espié, M., de Reyniès, A., Feugeas, J.-P., Plassa, L.-F., Soliman, H., Varna, M., de Roquancourt, A., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040090 · Cited by 173
Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation
Figueiredo, B. C., Sandrini, R., Zambetti, G. P., Pereira, R. M., Cheng, C., Liu, W., Lacerda, L., Pianovski, M. A., Michalkiewicz, E., Jenkins, J., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030551 · Cited by 166
Hussain, S. P., & Harris, C. C. (1999) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 163
Self-citationRecent advances in p53 research: an interdisciplinary perspective
Olivier, M., Petitjean, A., Marcel, V, Pétré, A., Mounawar, M., Plymoth, A., de Fromentel, C. C., & Hainaut, P. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.69 · Cited by 161
Erber, R., Conradt, C., Homann, N., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201690 · Cited by 157
Temam, S., Flahault, A., Périé, S., Monceaux, G., Coulet, F., Callard, P., Bernaudin, J., Guily, J. L. S., & Fouret, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.385 · Cited by 153
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
Matakidou, A., Eisen, T., & Houlston, R. S. (2003) · Mutagenesis · doi:10.1093/mutage/geg008 · Cited by 151
p53 Codon 72 Polymorphism and Cervical Neoplasia
Koushik, A., Platt, R. W., & Franco, E. L. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-083-3 · Cited by 147
Hussain, S. P., Amstad, P., Raja, K., Sawyer, M., Hofseth, L. J., Shields, P. G., Hewer, A. J., Phillips, D. H., Ryberg, D., Haugen, A., et al. (2001) · PubMed · Cited by 147
Self-citationNenutil, R., Šmardová, J., Pavlová, Š., Hanzelková, Z., Müller, P., Fabián, P., Hrstka, R., Janotova, P., Radina, M., Lane, D. P., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1838 · Cited by 135
p53 and K-ras mutations in lung cancers from former and never-smoking women.
Vähäkangas, K., Bennett, W. P., Castrén, K., Welsh, J. A., Ma, K., Blömeke, B., Alavanja, M. C. R., & Harris, C. C. (2001) · PubMed · Cited by 128
Self-citationMicroRNA-Cancer Connection: The Beginning of a New Tale
Calin, G. A., & Croce, C. M. (2008) · AACR Education book · doi:10.1158/aacr.edb-can-06-0800 · Cited by 120
Iacopetta, B. M., Russo, A. D., Bazan, V., Dardanoni, G., Gebbia, V., Soussi, T., Kerr, D. J., Elsaleh, H., Soong, R., Kandioler, D., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl035 · Cited by 119
Stern, M. C., Umbach, D. M., Yu, M. C., London, S. J., Zhang, Z., & Taylor, J. A. (2001) · PubMed · Cited by 112
Clinical Implications of the p53 Tumor-Suppressor Gene
Müller, M., Volkmann, M., Zentgraf, H., & Galle, P. R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301215 · Cited by 110
Hashimoto, T., Tokuchi, Y., Hayashi, M., Kobayashi, Y., 西田, 一., Hayashi, S., Ishikawa, Y., Tsuchiya, S., Nakagawa, K., Hayashi, J., et al. (1999) · PubMed · Cited by 109
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
de Graeff, P., Crijns, A. P. G., de Jong, S., Boezen, M., Post, W. J., de Vries, E. G. E., van der Zee, A. G. J., & de Bock, G. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605112 · Cited by 108
Alsner, J., Jensen, V., Kyndi, M., Offersen, B. V., Vu, P., Børresen‐Dale, A., & Overgaard, J. (2008) · Acta Oncologica · doi:10.1080/02841860802047411 · Cited by 107
Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients
Jackson, P. E. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg101 · Cited by 105
Nitric oxide and p53 in cancer‐prone chronic inflammation and oxyradical overload disease
Goodman, J. E., Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20024 · Cited by 99
Self-citationSzymańska, K., Lesi, O. A., Kirk, G. D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20103 · Cited by 93
oden-Gangloff, A., Fiore, F. D., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière‐Michot, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 91
Aflatoxin Exposure and Viral Hepatitis in the Etiology of Liver Cirrhosis in The Gambia, West Africa
Kuniholm, M. H., Lesi, O. A., Mendy, M. E., Akano, A. O., Sam, O., Hall, A. J., Whittle, H. C., Bah, E., Goedert, J. J., Hainaut, P. L., et al. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.11661 · Cited by 90
Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway
Zenz, T., Benner, A., Döhner, H., & Stilgenbauer, S. (2008) · Cell Cycle · doi:10.4161/cc.7.24.7245 · Cited by 85
Prognostic Significance of p53 Codon 72 Polymorphism Differs with Race in Colorectal Adenocarcinoma
Katkoori, V. R., Xu, J., Shanmugam, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1719 · Cited by 83
Allelic frequency of a p53 polymorphism in human lung cancer.
Weston, A., Perrin, L. S., Forrester, K., Hoover, R. N., Trump, B. F., Harris, C. C., & Caporaso, N. E. (1992) · PubMed · Cited by 83
Self-citationExpression of p53 isoforms in squamous cell carcinoma of the head and neck
Boldrup, L., Bourdon, J., Coates, P. J., Sjöström, B., & Nylander, K. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.019 · Cited by 81
Lim, E. H., Zhang, S.-L., Li, J., Yap, W. S., Howe, T.-C., Tan, B. P., Lee, Y.-S., Wong, D., Khoo, K., Seto, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913e28 · Cited by 77
Bazan, V., Agnese, V., Corsale, S., Calò, V., Valerio, M. R., Latteri, M. A., Vieni, S., Grassi, N., Cicero, G., Dardanoni, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi908 · Cited by 77
Ludovini, V., Pistola, L., Gregorc, V., Floriani, I., Rulli, E., Piattoni, S., Carlo, L. D., Semeraro, A., Darwish, S., Tofanetti, F. R., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168c7d0 · Cited by 75
Mechanic, L. E., Bowman, E. D., Welsh, J. A., Ma, K., Hagiwara, N., Enewold, L., Shields, P. G., Burdette, L. A., Chanock, S. J., & Harris, C. C. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0790 · Cited by 73
Self-citationBenjamin, C. L., Ullrich, S. E., Kripke, M. L., & Ananthaswamy, H. N. (2007) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00213.x · Cited by 71
Polymorphisms in XPD and TP53 and mutation in human lung cancer
Mechanic, L. E., Marrogi, A. J., Welsh, J. A., Bowman, E. D., Khan, M. A., Enewold, L., Zheng, Y.-L., Chanock, S., Shields, P. G., & Harris, C. C. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh344 · Cited by 62
Self-citationBeyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations
Gonzalez, K. D., Noltner, K., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Ngyuen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11031 · Cited by 58
Che, M., DeSilvio, M., Pollack, A. S., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.070 · Cited by 43
Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers
Hagiwara, N., Mechanic, L. E., Trivers, G. E., Cawley, H., Taga, M., Bowman, E. D., Kumamoto, K., He, P., Bernard, M., Doja, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0991 · Cited by 37
Self-citationFouquet, C., Antoine, M., Tisserand, P., Favis, R., Wislez, M., Commo, F., Rabbe, N., Carette, M. F., Milleron, B. J., Barany, F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0994-03 · Cited by 36
Koshiol, J. E., Hildesheim, A., González, P., Bratti, M. C., Porras, C., SCHIFFMAN, M. H., Herrero, R., Rodríguez, A. C., Wacholder, S., Yeager, M., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0830 · Cited by 34
Cancer-prone oxyradical overload disease.
Ambs, S., Hussain, S. P., Marrogi, A. J., & Harris, C. C. (1999) · PubMed · Cited by 30
Self-citationIs There a Role for Routine p53 Testing in Colorectal Cancer?
Hoff, P. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.021 · Cited by 14
Cited by
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
Interaction between the microbiome and TP53 in human lung cancer
Greathouse, K. L., White, J. R., Vargas, A. J., Bliskovsky, V. V., Beck, J. A., von Muhlinen, N., Polley, E. C., Bowman, E. D., Khan, M. A., Robles, A. I., et al. (2018) · Genome Biology · doi:10.1186/s13059-018-1501-6 · Cited by 446
Self-citationp53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
TP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 388
Metadata
- Authors
- Robles, A. I., & Harris, C. C.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-11-25
- Volume
- 2
- Issue
- 3
- Pages
- a001016-a001016
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2167097026
- Cited by
- 394
- References
- 99
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.